Conduit Pharmaceuticals Valuation
| CDTTW Stock | 0.01 0.0004 6.35% |
Conduit Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Conduit Pharmaceuticals from analyzing the firm fundamentals such as EBITDA of (324 K), total debt of 985 K, and Return On Asset of -3.22 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Conduit Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Conduit Pharmaceuticals is based on 3 months time horizon. Increasing Conduit Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Conduit stock is determined by what a typical buyer is willing to pay for full or partial control of Conduit Pharmaceuticals. Since Conduit Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Conduit Stock. However, Conduit Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0059 | Real 0.005664 | Hype 0.006133 |
The intrinsic value of Conduit Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Conduit Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Conduit Pharmaceuticals helps investors to forecast how Conduit stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Conduit Pharmaceuticals more accurately as focusing exclusively on Conduit Pharmaceuticals' fundamentals will not take into account other important factors: Conduit Pharmaceuticals Total Value Analysis
Conduit Pharmaceuticals is currently anticipated to have takeover price of 0 with market capitalization of 0, debt of 985 K, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Conduit Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the companyConduit Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Conduit is to check how much profit was generated for every dollar of assets it reports. Conduit Pharmaceuticals shows a negative utilization of assets of -3.22 percent, losing USD0.0322 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Conduit Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Conduit Pharmaceuticals Profitability Analysis
Net Loss for the year was (535 K) with profit before overhead, payroll, taxes, and interest of 0.About Conduit Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Conduit Pharmaceuticals. We calculate exposure to Conduit Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Conduit Pharmaceuticals's related companies.Conduit Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Conduit Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 67.9 M |
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.